Windham Capital Partners Research
Investment Thesis
Windham Capital Partners invests in people solving difficult problems and building category-defining products in healthcare. Founded on the conviction that the strongest returns come from backing visionary leaders at the intersection of medical technology and digital health, the firm combines deep healthcare domain expertise with operational support to help portfolio companies transform healthcare delivery and improve patient outcomes.
Core Investment Principles
Relationships: Windham's unique network spans pharmaceutical, medical device, and digital health markets, connecting entrepreneurs with industry experts, clinicians, and thought leaders. Strategic relationships are core to the firm's DNA and investment process.
Evidence-Based Innovation: The fund emphasizes technology and products that are evidence-based, either transformative in approach or clearly superior to existing solutions, free from IP barriers, and addressing large unmet needs in healthcare.
Operational Excellence: Beyond capital, Windham provides operational support, connecting portfolio companies with their extensive network of advisors, clinical experts, and successful healthcare entrepreneurs.
Stage and Check Size
Windham primarily invests in early-stage healthcare companies:
- Target stages: Seed and Series A
- Typical check size: $1M-$5M
- Check range: $1M minimum to $5M+ for strong follow-ons
- Investment style: Lead or co-lead rounds in most cases
The fund focuses on companies beyond the concept stage that have generated impressive data demonstrating their technology works and understand healthcare economics with a clear value proposition.
Investment Criteria
Windham's investment committee evaluates opportunities based on three core standards:
1. Leadership Team
- Right experience, knowledge, expertise and resources
- Honest and realistic about company challenges
- Track record in healthcare or relevant domain
2. The Company
- Beyond concept development stage
- Addresses large unmet need in healthcare
- Focused on "the next big thing" in a large market
- Generated impressive data demonstrating technology/product works
- Clear understanding of healthcare economics and value proposition
3. Technology or Procedure
- Evidence-based approach
- Transformative or clearly superior to existing products
- Free of intellectual property barriers
- Clear path to commercialization
Sector and Model Focus
Primary Sectors:
- Medical Devices and Diagnostics (45% of portfolio)
- Digital Health and Healthcare IT (35%)
- Biotech and Life Sciences (20%)
Specific Focus Areas:
- Surgical devices and minimally invasive procedures (cardiology, orthopedics, neurology)
- Diagnostic and monitoring technologies (liquid biopsies, continuous glucose monitoring, digital imaging)
- Digital health platforms (medication management, mental health, care coordination)
- Precision medicine and personalized diagnostics
- Healthcare payment and access solutions
- Wearable and implantable technologies
Geographic Focus
Primary markets: United States (especially Northeast corridor where firm is based in NYC) Secondary markets: Selected opportunities in Western Europe and other developed healthcare systems
Recent Activity (2025)
Latest Investment: August 27, 2025 - Co-led majority growth recapitalization in PainTEQ (interventional spine care device company) alongside Signet Healthcare Partners
Fund Status: Actively deploying from current fund Portfolio Momentum: Continuing to invest in both new opportunities and growth rounds for existing portfolio companies
Portfolio Highlights
IPOs:
- Alto Neuroscience (clinical-stage biopharma for mental health)
- CVRx (implantable device for hypertension and heart failure treatment)
- NovoCure (tumor treatment fields cancer therapy, NASDAQ: NVCR)
- Invuity (surgical visualization systems, acquired by Stryker)
Notable Acquired Companies:
- Cartiva (osteoarthritis/musculoskeletal solutions, acquired)
- Locemia (diabetes pharmaceutical, needle-free hypoglycemia rescue)
- MC10 (wearable electronics, acquired)
- Nebula Genomics (genome sequencing marketplace, acquired)
- NeoTract (benign prostatic hyperplasia treatment)
- PGDx/Personal Genome Diagnostics (precision oncology diagnostics)
- Science Exchange (scientific collaboration marketplace)
Active Portfolio (50+ companies):
- Alto Neuroscience, Andros, BlueprintHealth, Coravin, CVRX, Cartiva, ChromaCode, Clever Care, ControlRad, Cureatr, DOTS, Delfi Diagnostics, Earlens, Fore Biotherapeutics, GlySens, Invuity, Nebula Genomics, NeoTract, NeuSpera, NovoCure, Nuvaira, PainTEQ, RxWare, SubjectWell, TailorMed, Upward Health, Valera Health, Vergent Bioscience, WellDoc, Willow (Breast Pump), and others
Team and Expertise
Founders & Leadership:
-
Roger Fine, Chairman and Co-Founder: Former General Counsel of Johnson & Johnson (30-year career), member of J&J Executive Committee for 15 years. Chairman of Robert Wood Johnson Foundation (3rd largest US foundation, largest devoted to healthcare). Law degree from NYU.
-
Adam Fine, General Partner and CEO: Co-Founder and CEO, currently board director at multiple portfolio companies. Previously VP & GM at I-many, Inc. (healthcare software), business development at J&J ventures (Cordis, Biosense).
-
David Kereiakes, Managing Partner: Joined 2023 from Providence Ventures. Extensive track record leading or co-leading investments resulting in $1B+ in value creation. Board member of multiple healthcare companies.
-
Joe Proto, Co-Founder: Launched REMITCO (acquired by First Data 2000) and CashFlex (acquired 1992). CEO of Transactis Inc. Expert in payments and healthcare billing.
Operating Partners & Advisors:
- Jason Helgerson: Former NYS Medicaid Director (ran $70B program), Wisconsin Medicaid Director, founder of Helgerson Solutions Group
- Dr. Alistair Erskine, MD: Chief Digital Health Officer at Emory Healthcare, former Chief Digital Health Officer at Mass General Brigham, MBA from MIT Sloan
- Dr. Deneen Vojta, MD: EVP Research & Development at UnitedHealth Group, former CEO of Alliance Health Solutions
- Lorne Taichman, PhD, MD: Director of Science & Technology, 30-year research career in stem cells and gene therapy, 60+ peer-reviewed publications, NIH MERIT award recipient
- Laura Sage: Director of Marketing & Investor Relations, background in finance and healthcare partnerships
- Bill Crouse: Retired MGP of HealthCare Ventures (100+ companies, $60B+ combined market cap), board director at multiple biotech companies
- Allan Bufferd: Former CIO of MIT (19 years), Treasurer Emeritus, board director at Beth Israel Deaconess Medical Center
- Jeffrey A. Sachs: Healthcare policy expert (30+ years), founder of Sachs Policy Group
- Sara Vaezy: EVP Chief Strategy & Digital Officer at Providence Health (52 hospitals, 1,085 clinics), architect of Digital Innovation Group
Lead Tendency and Decision Process
Lead Tendency: Leads or co-leads most investments in portfolio companies where the firm takes significant ownership stake
Decision Process: Partnership-based model with input from co-founders and relevant operating partners/advisors based on domain expertise
Decision Timeline: Typically 2-3 months from initial discussion to investment decision for Seed-stage companies
Warm Intro Preference: Yes - relationships are core to investment process; warm introductions from network greatly facilitate engagement
Founder Preferences
Windham backs healthcare leaders with:
- Deep domain expertise and experience in healthcare/medtech
- Track record of building successful companies or leading initiatives
- Ability to attract world-class teams
- Realistic understanding of regulatory and commercialization challenges
- Passion for solving unmet medical needs
- Strong scientific or clinical foundation (for biotech/medtech)
Portfolio Company Support
Beyond capital, Windham provides:
- Strategic introductions to clinical experts, hospital systems, and care delivery organizations
- Operational guidance on healthcare commercialization, reimbursement, and regulatory strategy
- Connections to manufacturing, supply chain, and quality partners
- Board representation and governance expertise
- Access to healthcare policy experts and regulators
Fund Status and AUM
- Current Focus: Actively deploying capital
- Fund Size: Multiple successful funds with estimated $500M+ under management based on portfolio size and investment activity
- Investment Frequency: 3-4 new investments per year
- Geographic Bias: US-focused with strong Northeast presence
Decision Factors and Anti-Thesis
What Windham Backs:
- Evidence-based innovation addressing large healthcare markets
- Companies with realistic paths to significant exits (IPO or acquisition)
- Teams with healthcare domain expertise
- Technologies with clear clinical or economic advantages
- Early-stage companies that have achieved meaningful validation
What Windham Avoids:
- Early-concept stage companies without meaningful data
- Me-too products without clear differentiation
- Companies with significant IP encumbrance
- Teams without healthcare industry experience
- Business models that don't understand healthcare economics
- Single-market or limited addressable market opportunities
Competitive Positioning
Windham differentiates through:
- Domain expertise: Operating partners include hospital system executives, health policy experts, clinical leaders, and successful healthcare entrepreneurs
- Network access: Two-decade reputation in healthcare investing provides unique access to clinical experts, hospital systems, and industry leaders
- Operational support: Hands-on approach with board seats, operating partner involvement, and strategic guidance
- Exit track record: Multiple successful IPOs and strategic acquisitions demonstrate ability to shepherd companies to significant outcomes
- Healthcare economics expertise: Team understands reimbursement, regulatory, and healthcare delivery dynamics that are critical to healthcare company success